Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Congenital cardiac disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    169 result(s) found for: Congenital cardiac disorders. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2007-000390-31 Sponsor Protocol Number: HyperHAES-PÄD-CARDIO-02 Start Date*: 2007-10-30
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Application of hypertonic hyperoncotic solutions for improvement of cardiac output after open heart surgery in children - monocentric, randomised, placebo controlled, double-blind clinical trial (p...
    Medical condition: Children after open-heart surgery for congenital cardiac disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019273 Heart disease congenital LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005239-14 Sponsor Protocol Number: 062011 Start Date*: 2012-01-05
    Sponsor Name:Pertti Suominen [...]
    1. Pertti Suominen
    2. Pertti Suominen
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10010495 Congenital heart disease NOS LLT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000946-38 Sponsor Protocol Number: EFC5314 Start Date*: 2007-01-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: International randomized double blind clinical study evaluating the efficacy and safety of clopidogrel 0.2mg/kg once daily versus placebo in neonates and infants with cyanotic congenital heart dise...
    Medical condition: Neonates or infants (age less than or equal to 92 days at the time of randomization) with systemic to pulmonary arterial shunt for palliation of cyanotic congenital heart disease.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019273 Heart disease congenital LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) FI (Completed) SE (Completed) DK (Completed) PT (Completed) FR (Completed) HU (Completed) IT (Completed) NL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-004596-31 Sponsor Protocol Number: NL62772 Start Date*: 2019-03-25
    Sponsor Name:UMC Utrecht
    Full Title: CeRebrUm and CardIac protection with Allopurinol in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass
    Medical condition: Brain injury in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010495 Congenital heart disease NOS LLT
    20.0 10029205 - Nervous system disorders 10067967 Brain injury PT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-004999-53 Sponsor Protocol Number: LTS10916 Start Date*: 2009-02-06
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Long-term safety study in patients included in CLARINET study with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt and for whom the shunt is still in place at...
    Medical condition: Patients at one year of age who are included in CLARINET, with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt, and for whom the shunt is still in place.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019273 Heart disease congenital LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) ES (Completed) BE (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-007042-18 Sponsor Protocol Number: CHD Vasovist Start Date*: 2007-03-08
    Sponsor Name:Kings College London [...]
    1. Kings College London
    2. Guy's & St Thomas'NHS Foundation Trust
    Full Title: Improved Diagnosis of Congenital Heart Disease by MRI using Vasovist - CHD Vasovist
    Medical condition: Congenital Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010495 Congenital heart disease NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001784-77 Sponsor Protocol Number: ML6721 Start Date*: 2012-05-07
    Sponsor Name:University Hospitals Leuven
    Full Title: Fontan patients: Comprehensive evaluation of the pulmonary circulation to identify pulmonary vascular disease and its influence on ventricular hemodynamics.
    Medical condition: Fontan patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10010495 Congenital heart disease NOS LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007413-76 Sponsor Protocol Number: steroiditutkimus Start Date*: 2009-02-27
    Sponsor Name:Pertti Suominen
    Full Title: Metyyliprednisolonin farmakokinetiikka ja -dynamiikka lasten avosydänleikkausten yhteydessä
    Medical condition: Lasten ja nuorten sairaalassa (HUS) hoidettavat 1-12 kk ikäiset avosydänleikkaukseen tulevat potilaat, joilla on sydänvikanan TOF, AVSD tai VSD. Lasten ja nuorten sairaalassa (HUS) hoidettavat ko...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010495 Congenital heart disease NOS LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001189-40 Sponsor Protocol Number: 3 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Tartu
    Full Title: PHARMACOKINETICS OF ORAL SPIRONOLACTONE IN CHILDREN UP TO 2 YEARS OF AGE
    Medical condition: cardiac failure, ascites and/or oedema
    Disease: Version SOC Term Classification Code Term Level
    17.0 10007541 - Cardiac disorders 10010394 Congenital cardiac disorders HLGT
    17.0 10018065 - General disorders and administration site conditions 10049630 Oedema due to renal disease PT
    17.0 10018065 - General disorders and administration site conditions 10030103 Oedema generalized LLT
    17.0 10017947 - Gastrointestinal disorders 10003445 Ascites PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004343-80 Sponsor Protocol Number: 545.12 Start Date*: 2012-09-20
    Sponsor Name:OSPEDALE PEDIATRICO BAMBINO GESU' DI ROMA
    Full Title: STUDY PHASE III, RANDOMIZED, DOUBLE-BLIND CONTROLLED TO EVALUATE THE EFFECTIVENESS OF FUROSEMIDE IN CONTINUOUS INFUSION VS ethacrynic acid IN CONTINUOUS INFUSION IN CHILDREN SUBJECT TO A heart sur...
    Medical condition: ALL CHILDREN AGE 'LESS THAN 10 YEARS OF AGE' WITH CONGENITAL HEART PROCEDURE SUBJECT TO cardiac surgery in whom the diuretic ARE GIVEN IN ACCORDANCE WITH THE FOLLOWING CONTINUOUS INFUSION PROTOCOL ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002396-18 Sponsor Protocol Number: 2015-602295-02 Start Date*: 2015-11-30
    Sponsor Name:Ethicare GmbH
    Full Title: ORODISPERSIBLE MINITABLETS OF ENALAPRIL IN YOUNG CHILDREN WITH HEART FAILURE DUE TO CONGENITAL HEART DISEASE
    Medical condition: Heart Failure due to Congenital Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10010495 Congenital heart disease NOS LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) GB (Prematurely Ended) NL (Ongoing) AT (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-001247-39 Sponsor Protocol Number: CV185-362 Start Date*: 2017-04-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or LMWH in Pediatric Subjects with Congenital or Acquired Heart ...
    Medical condition: Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10019273 Heart disease congenital PT
    20.0 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    20.0 10007541 - Cardiac disorders 10019276 Heart disease, unspecified LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    20.0 10047065 - Vascular disorders 10023320 Kawasaki's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) FI (Completed) AT (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003325-10 Sponsor Protocol Number: 1.01 Start Date*: 2012-08-10
    Sponsor Name:VU University Medical Center
    Full Title: A randomized controlled trail on the effects of periconceptional and prenatal folic acid supplementation on congenital anomalies and preterm birth
    Medical condition: congenital anomalies
    Disease: Version SOC Term Classification Code Term Level
    14.1 10036585 - Pregnancy, puerperium and perinatal conditions 10004953 Birth premature LLT
    14.1 10010331 - Congenital, familial and genetic disorders 10007607 Cardiac septal defects congenital HLT
    14.1 10010331 - Congenital, familial and genetic disorders 10041524 Spina bifida PT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003532-68 Sponsor Protocol Number: FIBCON Start Date*: 2014-03-11
    Sponsor Name:Guy's and St Thomas NHS Foundation Trust
    Full Title: Fibrinogen concentrate supplementation in the management of bleeding during paediatric cardiopulmonary bypass: a phase 1B/2A, open label dose escalation study (Version 1.0, Jan 28, 2014)
    Medical condition: Neonates and infants who are at risk of mediastinal bleeding following cardiopulmonary bypass surgery for congenital heart disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10055817 Haemorrhage intrapericardial LLT
    16.1 100000004850 10010495 Congenital heart disease NOS LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010404-28 Sponsor Protocol Number: G83627057 Start Date*: 2009-06-12
    Sponsor Name:Fundación de Investigación Biomédica del Hospital Universitario La Paz, Madrid
    Full Title: PREVENCIÓN DEL SÍNDROME DE BAJO GASTO POSTOPERATORIO EN RECIÉN NACIDOS SOMETIDOS A CIRUGÍA CARDIOVASCULAR: ESTUDIO PILOTO SOBRE LA FARMACOCINÉTICA Y FARMACODINAMIA DOSIS-DEPENDIENTE DE DOS INODILA...
    Medical condition: Este estudio evaluará la eficacia de dos inodilatadores (IND) en el tratamiento del síndrome de bajo gasto postoperatorio (SBGP) en recién nacidos sometidos a cirugía cardiovascular (CCV)
    Disease: Version SOC Term Classification Code Term Level
    9 10024899 Low cardiac output syndrome LLT
    9 10010495 Congenital heart disease NOS LLT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002856-33 Sponsor Protocol Number: ALN-TTRSC-002 Start Date*: 2013-11-15
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac Amyloidosis
    Medical condition: Transthyretin (TTR) Cardiac Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001229-34 Sponsor Protocol Number: ALN-TTRSC-003 Start Date*: 2014-08-01
    Sponsor Name:Alnylam Pharmaceuticals, Inc.
    Full Title: A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients with Transthyretin (TTR) Cardiac Amyloidosis Who Have Previo...
    Medical condition: Transthyretin (TTR) Cardiac Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004068-74 Sponsor Protocol Number: ZEPLAST-PED Start Date*: 2019-09-26
    Sponsor Name:I.R.C.C.S. POLICLINICO SAN DONATO
    Full Title: ZEro_PLASma Trial in small infants undergoing cardiac surgery
    Medical condition: Congenital heart disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002397-21 Sponsor Protocol Number: 2015-602295-03 Start Date*: 2015-11-30
    Sponsor Name:Ethicare GmbH
    Full Title: FOLLOW-UP SAFETY TRIAL IN CHILDREN WITH CHRONIC HEART FAILURE THERAPY RECEIVING ORODISPERSIBLE MINITABLETS OF ENALAPRIL
    Medical condition: Heart Failure due to Dilated Cardiomyopathy and Congenital Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10010495 Congenital heart disease NOS LLT
    18.1 100000004849 10056419 Dilated cardiomyopathy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) AT (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002157-38 Sponsor Protocol Number: 57911 Start Date*: 2017-09-14
    Sponsor Name:Radboud University Medical Center
    Full Title: Treatment of congenital vascular malformations using Sirolimus: improving quality of Life
    Medical condition: congenital vascular malformation : Vascular malformations can involve lymphatic vessels, capillaries, veins and arteries or even combinations. These vascular malformations are present at birth an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000005125 10047091 Vascular malformations and acquired anomalies HLT
    20.0 100000158692 10047090 Vascular malformation peripheral LLT
    20.0 10017947 - Gastrointestinal disorders 10070181 Gastrointestinal vascular malformation PT
    20.0 10010331 - Congenital, familial and genetic disorders 10074979 Vascular malformation PT
    Population Age: Infants and toddlers, Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:37:40 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA